OTC Bulletin Board S & P Company Insight for CORTEX PHARM INC D9
Profile
	Business Summary: Cortex Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders.   Address   15241 Barranca Parkway   Irvine , CA 92618   Phone: 949-727-3157   Fax: 949-727-3657   Website: http://www.cortexpharm.com Transfer Agent   American Stock Transfer & Trust Co. Employees:  27 ShareHolders:  9500 Founded:  1987 Domicile:  Delaware
Background
	Cortex Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company develops AMPAKINE compounds for the treatment of Alzheimer's disease, mild cognitive impairment, attention deficit hyperactivity disorder, schizophrenia, depression, respiratory depression caused by opiate analgesics, and possibly sleep apnea. Its low impact AMPAKINE compounds include CX717 and CX1739, which are in phase II clinical development stage; and high impact compounds include CX929 for Huntington's disease patients. The company has a research collaboration and exclusive worldwide license agreement with NV Organon to develop and commercialize its AMPAKINE technology for the treatment of schizophrenia and depression. Cortex Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California. History:  INCORPORATED in Delaware Feb. 10, 1987 as X-Age, Inc. Name changed to Cortex Pharmaceuticals, Inc. in August 1988.   Subsidiaries: Cortex UK Limited Orchid Acquisition Corp. Rose Acquisition Corp.     Capital Expenditures, thousand. US Dollars   Year   Amount   2008   124   2007   550   2006   100   Research and Development Expenditures, thousand. US Dollars   Year   Amount   2008   10,780   2007   9,327   2006   13,262
Management
	Management Officers Position  Roger G. Stoll Chairman  Mark  Varney President & Chief Executive Officer  Maria S. Messinger Secretary, Controller, Chief Accounting Officer & Chief Financial Officer  Damian R. McIntosh Investor Relations Contact Directors  Robert F. Allnutt  John F. Benedik  Charles J. Casamento  Carl W. Cotman  Peter F. Drake  M. Ross Johnson  Roger G. Stoll  Mark  Varney
Annual Report
	Annual Report   Income Statement   2008 2007 2006 REVENUES Grant Revenues - - 26,851 Research, License and Grant Revenues - - 1,150,608 Total Revenues - - 1,177,459 EXPENSES General and Administrative Expenses (4,258,603) (4,319,918) (4,616,312) Research and Development (10,780,324) (9,327,298) (13,261,768) Net Interest Income/expense 443,061 678,053 645,820 Earnings before Taxes (14,595,866) (12,969,163) (16,054,801) TAXES AND OTHER EXPENSES Net Income (Loss) (14,595,866) (12,969,163) (16,054,801) SUPPLEMENTARY INFO Operating Income (Loss) (15,038,927.00) (13,647,216.00) (16,700,621.00) Basic Eps-continuing Operations (0.31) (0.31) (0.47)   Balance Sheet   2008 2007 CURRENT ASSETS Cash and Cash Equivalents 1,430,886 4,020,881 Marketable Securities 2,710,434 13,263,560 Other Current Assets 154,884 246,960 Total Current Assets 4,296,204 17,531,400 NON CURRENT ASSETS Furniture, Equipment and Leasehold Improvements, Net 809,458 850,647 Other Assets 46,667 46,667 Total Assets 5,152,329 18,428,716 CURRENT LIABILITIES Accounts Payable 1,123,015 970,702 Accrued Wages, Salaries and Related Expenses 293,746 398,344 Deferred Rent 27,123 52,226 Advance for Mci Project 311,723 305,422 Total Current Liabilities 1,755,607 1,726,694 NON CURRENT LIABILITIES Preferred Stock Convertible 21,703 21,703 Other Non-current Liability - 25,119 SHAREHOLDERS' EQUITY Common Stock-par Value 47,615 47,542 Additional Paid in Capital 112,686,080 111,339,504 Accumulated Deficit (109,354,792) (94,758,928) Unrealized Gain/loss on Available for Sale U.S. Government Securities (3,884) 27,073 Total Shareholders Equity 3,396,722 16,676,902 Total Liabilities & Shareholders Equity 5,152,329 18,428,716
Interim Report
	Interim Report      Data Not Available
Pro Forma Report
	Pro Forma Report      Data Not Available
Quarterly Report
	Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2007   1 Nil   2007   2 Nil   2007   3 Nil   2006   1 230,000   2006   2 230,000   2006   3 400,000   2006   4 310,000   2006   Full Year 1,180,000   2005   1 670,000   2005   2 650,000   2005   3 630,000   2005   4 610,000   2005   Full Year 2,580,000   2004   1 1,340,000   2004   2 3,260,000   2004   3 1,170,000   2004   4 1,210,000   2004   Full Year 4,280,000     Quarterly Net Income, US$ Year Quarter Revenue   2009   1 (3,170,000)   2009   2 (1,950,000)   2009   3 (1,730,000)   2008   1 (4,370,000)   2008   2 (3,950,000)   2008   3 (3,150,000)   2008   4 (3,130,000)   2008   Full Year (14,600,000)   2007   1 (3,880,000)   2007   2 (2,850,000)   2007   3 (2,960,000)   2007   4 (3,270,000)   2007   Full Year (12,970,000)   2006   1 (4,560,000)   2006   2 (4,400,000)   2006   3 (3,630,000)   2006   4 (3,460,000)   2006   Full Year (16,054,800)   2005   1 (2,650,000)   2005   2 (2,690,000)   2005   3 (2,530,000)   2005   4 (3,740,000)   2005   Full Year (11,605,700)   2004   1 (4,320,000)   2004   2 510,000   2004   3 (870,000)   2004   4 (1,310,000)   2004   Full Year (4,046,200)     Quarterly EPS, US$ Year Quarter Revenue   2009   1 (.07)   2009   2 (.06)   2009   3 (.06)   2008   1 (.09)   2008   2 (.08)   2008   3 (.07)   2008   4 (.07)   2008   Full Year (.31)   2007   1 (.10)   2007   2 (.07)   2007   3 (.07)   2007   4 (.07)   2007   Full Year (.31)   2006   1 (.14)   2006   2 (.13)   2006   3 (.10)   2006   4 (.10)   2006   Full Year (.47)   2005   1 (.08)   2005   2 (.08)   2005   3 (.08)   2005   4 (.11)   2005   Full Year (.36)   2004   1 (.24)   2004   2 .02   2004   3 (.03)   2004   4 (.05)   2004   Full Year (.26)
Stock Data
	Capitalization as of 03/31/2009:     Authorized Shares Outstanding Shares Common $0.001 par 105,000,000 47,615,209 Preferred $0.001 par 5,000,000 37,500so2   LONG TERM DEBT: None.   Common $0.001 par   Stockholders:  04/10/2009, 9500. Transfer Agent:  American Stock Transfer & Trust Co.   New York , NY   OTC Bulletin Board( Primary): CORX   Exchange Year High Low OTC Bulletin Board 2009 0.6300 0.0700 NYSE Amex 2008 1.2400 0.4100 American Stock Exchange 2007 3.4700 0.4400 American Stock Exchange 2006 5.9400 1.1890 American Stock Exchange 2005 3.0300 1.9600 American Stock Exchange 2004 4.1700 1.4000 American Stock Exchange 2003 4.9900 0.6000 American Stock Exchange 2002 3.4400 0.5100 American Stock Exchange 2001 3.3000 1.4300 OTC Bulletin Board 2000 8.1250 0.6900   RECENT DIVIDENDS: Common $0.001 par: None.       so2Closely held. Consists of Series B Convertible shares, each share of which is convertible into approximately 0.09812 Common share. Liquidation preference and company redemption value, $0.6667 per share.